Carisma Therapeutics, Inc. ( (CARM) ) has released its Q1 earnings. Here is a breakdown of the information Carisma Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Carisma Therapeutics, Inc. is a biotechnology company focused on developing therapies for serious diseases, including liver fibrosis and cancer, using its proprietary platform of engineered macrophages and monocytes. In its latest earnings report, Carisma Therapeutics highlighted a significant reduction in its workforce and a strategic shift towards exploring potential strategic alternatives to maximize value and prepare for a possible wind-down of operations. The company reported a net loss of $9.3 million for the first quarter of 2025, a decrease from the $19.0 million loss in the same period last year, attributed to reduced operating expenses. Despite collaboration revenues of $3.7 million, the company’s financial position remains precarious, with cash and cash equivalents of $7.7 million as of March 31, 2025. Looking ahead, Carisma Therapeutics is evaluating various strategic options, including asset sales or partnerships, to address its financial challenges and continue its mission of developing transformative therapies.